U.S. Digital Pathology Market - Databook 2025 to 2034

The U.S. digital pathology market size accounted for USD 369.77 million in 2024 and is predicted to touch around USD 1,365.76 million by 2034, growing at a CAGR of 13.95% from 2025 to 2034.

Highlights of the U.S. Digital Pathology Market

• By product, the device segment held a dominant presence in the market in 2024.
• By product, the software segment is expected to grow at the fastest rate in the market during the forecast period of 2025 to 2034.
• By type, the human pathology segment accounted for a considerable share of the market in 2024.
• By type, the veterinary pathology segment is projected to experience the highest growth rate in the market between 2025 and 2034.
• By application, the disease diagnosis segment led the U.S. digital pathology market.
• By application, the disease diagnosis segment is set to experience the fastest rate of market growth from 2025 to 2034.
• By end-use, the hospitals segment registered its dominance over the market in 2024.
• By end-use, the diagnostic labs segment is anticipated to grow with the highest CAGR in the market during the studied years.

Industry Valuation and Growth Rate Projection

The U.S. digital pathology market is exhibiting robust growth due to growing healthcare systems catering to a high demand for healthcare needs and better technology. Overall, many of the hospitals and laboratories in the U.S. are implementing digital imaging of tissue samples in place of glass slides to expedite results. With digital pathology, physicians are able to share images faster from anywhere in the country. Many pharmaceutical companies in the United States are using artificial intelligence (AI) in a growing number of clinics and institutions to help pathologists find diseases sooner and with greater accuracy, like cancer. There are many levels of the government furthering support for digital tools in healthcare, which will foster growth in the digital pathology market as well.

Some of the key players, like Philips in the U.S., along with Roche’s outreach in the U.S., are putting more focus on developing digital pathology solutions, which will lead to more competition. With the increasing number of people in the U.S. living with chronic diseases, there is a growing need for physicians to find a more timely and efficient way to review tissue specimens. The U.S. has excellent internet connectivity and access to cloud-based storage of medical data, that have helped advance the digital pathology market.

What are the Market Trends in the U.S. Digital Pathology Market?

The market trends in the United States digital pathology market are defined by government support through organizations such as the Food and Drug Administration, along with the rising use of artificial intelligence-based algorithms, speeding up the digital processes.

• FDA approvals for digital pathology systems (ex, Philips IntelliSite) will increase clinical use in hospitals.
• AI diagnostics are becoming mainstream to help physicians detect cancer and other diseases sooner than before.
• Remote pathology services are increasing, with U.S. labs bringing digital pathology services to rural communities.
• Mergers and partnerships among U.S. companies (ex, PathAI, Leica Biosystems) are developing better software and hardware solutions.

What are the Restraints in the U.S. Digital Pathology Market?

• The restraints in the U.S. digital pathology market are due to do with the high costs of implementation, due to expensive equipment, along with issues related to patient privacy and data security.
• Costly start-up prices for scanners, cloud storage, and AI tools make it difficult for smaller labs to adopt this.
• Data privacy laws require so much commitment to digital security, such as HIPAA, that it can also weigh down on the adoption of digital pathology.
• Insurance companies have a small risk reimbursement policy available for digital pathology services.

What are the Opportunities in the U.S. Digital Pathology Market?

There are many opportunities in the U.S. digital pathology market due to high demand and a robust healthcare infrastructure that allows for smoother implementation of new technology.

• Funding from the government for artificial intelligence and digital health projects is promoting user adoption and research.
• Growth of demand for personalized medicine based on digital pathology that matches patients to the correct treatment.
• Creation of cloud-based applications like Proscia's Concentriq to make it easier for laboratories to send images and evaluate their performance.

Recent Developments in the U.S. Digital Pathology Market:

• In January 2025, Roche announced that it had received FDA approval for their VENTATAN DP 600 slide scanner, which is a part of Roche’s Digital Pathology Dx system. The slide scanner can process 240 slides with quality images. These slide scanners help enhance diagnostic accuracy, consistency, and faster speed, providing high resolution images.
• In November 2023, PharmaNest Inc., Alimentiv Inc., and AcelaBio Inc. collaborated to revolutionize precision medicine and AI-based digital pathology for MASH (metabolic dysfunction-associated steatohepatitis)/NASH (nonalcoholic steatohepatitis) clinical trials.